Evidence map›Paper›PMID 35991621›Full record

ArticleEuropean heart journal supplements : journal of the European Society of Cardiology2022

Sympathetic activation in heart failure

E Gronda, V Dusi, E D'Elia, M Iacoviello, E Benvenuto, E Vanoli

Open access · bronzeAbstract read
In one paragraph

Article in European heart journal supplements : journal of the European Society of Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
8.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 63 citations in OpenAlex.

  1. Review
  2. An integrated overview of acute heart failure: a narrative review of pathophysiological mechanisms and contributing factors.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026
    Review
  3. Pleiotropic effects of renal denervation beyond blood pressure reduction.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Review
  4. Article
  5. Article
  6. The clinical value of circadian biofeedback in chronic heart failure.European heart journal. Digital health · 2026
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Modification of associations between ambient PMEnvironmental health : a global access science source · 2025
    Observational
  16. Review
  17. Trajectory of Cardiogenic Dementia: A New Perspective.Journal of cellular and molecular medicine · 2025
    Review
  18. Review
  19. Article
  20. Early experience with baroreflex activation therapy from a vascular surgery perspective.Journal of vascular surgery cases and innovative techniques · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 1 country.

E GrondaU.O.C. Nefrologia, Dialisi e Trapianto Renale dell'Adulto, Programma Cardiorenale, Dipartimento di Medicina e Specialità Mediche, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy.
V DusiCardiology Division, Department of Medical Sciences, University of Turin, Torino, Italy.
E D'EliaCardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy.
M IacovielloArea Cardiorenale Metabolica Associazione nazionale Medici Cardiologi Ospedalieri Italia.
E BenvenutoArea Cardiorenale Metabolica Associazione nazionale Medici Cardiologi Ospedalieri Italia.
E VanoliDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.
Associazione Nazionale Medici Cardiologi Ospedalieri · ITFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITOspedale Papa Giovanni XXIII · ITUniversity of Foggia · ITUniversity of Pavia · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sympathetic activation has been long appreciated exclusively as a fundamental compensatory mechanism of the failing heart and, thus, welcome and to be supported. In the initial clinical phases of heart failure (HF), the sympathetic nervous system overdrive plays a compensatory function aimed at maintaining an adequate cardiac output despite the inotropic dysfunction affecting the myocardium. However, when the sympathetic reflex response is exaggerated it triggers a sequence of unfavourable remodelling processes causing a further contractile deterioration that unleashes major adverse cardiovascular consequences, favouring the HF progression and the occurrence of fatal events. Eventually, the sympathetic nervous system in HF was demonstrated to be a 'lethality factor' and thus became a prominent therapeutic target. The existence of an effective highly specialized intracardiac neuronal network immediately rules out the old concept that sympathetic activation in HF is merely the consequence of a drop in cardiac output. When a cardiac damage occurs, such as myocardial ischaemia or a primary myocardial disorder, the adaptive capability of the system may be overcame, leading to excessive sympatho-excitation coupled with attenuation till to abolishment of central parasympathetic drive. Myocardial infarction causes, within a very short time, both a functional and anatomical remodelling with a diffuse up-regulation of nerve growth factor (NGF). The subsequent nerve sprouting signal, facilitated by a rise in the levels of NGF in the left stellate ganglion and in the serum, triggers an increase in cardiac nerve density in both peri-infarct and non-infarcted areas. Finally, NFG production decreases over time, supposedly as an adaptative response to the prolonged exposure to sympathetic overactivity, leading in the end to a reduction in sympathetic nerve density. Accordingly, NGF levels were markedly reduced in patients with severe congestive heart failure. The kidney is the other key player of the sympathetic response to HF as it indeed reacts to under-perfusion and to loop diuretics to preserve filtration at the cost of many pathological consequences on its physiology. This vicious loop ultimately participates to the chronic and disruptive sympathetic overdrive. In conclusion, sympathetic activation is the natural physiological consequence to life stressors but also to any condition that may harm our body. It is the first system of reaction to any potential life-threatening event. However, in any aspect of life over reaction is never effective but, in many instances, is, actually, life threatening. One for all is the case of ischaemia-related ventricular fibrillation which is, strongly facilitated by sympathetic hyperactivity. The take home message? When, in a condition of harm, everybody is yelling failure is just around the corner.

Indexed as

Autonomic nervous systemBaroreflex activationHeart failure

Identifiers

PMID35991621
PMCPMC9385124
OpenAlexW4292266459

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.